Market Cap 171.80M
Revenue (ttm) 0.00
Net Income (ttm) 1.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 84,300
Avg Vol 65,122
Day's Range N/A - N/A
Shares Out 43.27M
Stochastic %K 36%
Beta -0.28
Analysts Hold
Price Target $4.50

Company Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neur...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 600 7373
Address:
1500 District Avenue, Burlington, United States
Tony_37
Tony_37 Jan. 7 at 6:05 AM
$NERV : this is done .. 🔥
0 · Reply
GetRollz
GetRollz Jan. 6 at 7:26 PM
$NERV watching closely 🥸🥸🥸 https://www.stocktitan.net/news/NERV/minerva-neurosciences-announces-financing-of-up-to-200-million-to-pmp9dz6lcb9g.html
0 · Reply
GetRollz
GetRollz Jan. 6 at 7:07 PM
0 · Reply
GetRollz
GetRollz Jan. 6 at 6:57 PM
0 · Reply
GetRollz
GetRollz Jan. 6 at 6:57 PM
0 · Reply
GetRollz
GetRollz Jan. 6 at 6:56 PM
0 · Reply
FRAGMENTS
FRAGMENTS Jan. 5 at 7:37 PM
0 · Reply
FRAGMENTS
FRAGMENTS Jan. 5 at 12:31 PM
$SSP 📡 New FRAGMENTS (Paid): READ THE ECONOMY — 13D, 13G & Poison Pills Most people read markets through headlines. This piece reads them through ownership: who crossed 5%, who stayed “passive,” and which boards just pulled the poison pill off the shelf. This week’s tape (examples): GF, SCOR, ONTF, BNC, ZIM on the 13D side; IAS, LBRX, IKT, NERV, TNXP on 13G; plus defenses like SSP and TVE,TO. The point: filings often show intent before narrative — and boards defend when the quote starts to feel “in play.” HERE:https://cundilldeepvalue.substack.com/p/read-the-economy-13d-13g-and-board-576 $TVE.TO $TNXP $NERV
0 · Reply
Tony_37
Tony_37 Jan. 4 at 11:23 PM
$NERV : I will buy at $3.50 🚀💎
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 1 at 7:03 AM
0 · Reply
Latest News on NERV
Minerva Neurosciences: There's Probably Time For One More Rally

Aug 23, 2023, 4:05 AM EDT - 2 years ago

Minerva Neurosciences: There's Probably Time For One More Rally


Tony_37
Tony_37 Jan. 7 at 6:05 AM
$NERV : this is done .. 🔥
0 · Reply
GetRollz
GetRollz Jan. 6 at 7:26 PM
$NERV watching closely 🥸🥸🥸 https://www.stocktitan.net/news/NERV/minerva-neurosciences-announces-financing-of-up-to-200-million-to-pmp9dz6lcb9g.html
0 · Reply
GetRollz
GetRollz Jan. 6 at 7:07 PM
0 · Reply
GetRollz
GetRollz Jan. 6 at 6:57 PM
0 · Reply
GetRollz
GetRollz Jan. 6 at 6:57 PM
0 · Reply
GetRollz
GetRollz Jan. 6 at 6:56 PM
0 · Reply
FRAGMENTS
FRAGMENTS Jan. 5 at 7:37 PM
0 · Reply
FRAGMENTS
FRAGMENTS Jan. 5 at 12:31 PM
$SSP 📡 New FRAGMENTS (Paid): READ THE ECONOMY — 13D, 13G & Poison Pills Most people read markets through headlines. This piece reads them through ownership: who crossed 5%, who stayed “passive,” and which boards just pulled the poison pill off the shelf. This week’s tape (examples): GF, SCOR, ONTF, BNC, ZIM on the 13D side; IAS, LBRX, IKT, NERV, TNXP on 13G; plus defenses like SSP and TVE,TO. The point: filings often show intent before narrative — and boards defend when the quote starts to feel “in play.” HERE:https://cundilldeepvalue.substack.com/p/read-the-economy-13d-13g-and-board-576 $TVE.TO $TNXP $NERV
0 · Reply
Tony_37
Tony_37 Jan. 4 at 11:23 PM
$NERV : I will buy at $3.50 🚀💎
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 1 at 7:03 AM
0 · Reply
CoverageCap
CoverageCap Dec. 25 at 11:06 AM
$NERV The strategic path forward will be judged on practical milestones, not narrative strength. Cash generation and unit economics need to converge with strategy for the thesis to mature. Strategic clarity can reduce risk premiums even before growth accelerates. Investors will likely wait for pattern recognition before re‑committing capital.
0 · Reply
DonCorleone77
DonCorleone77 Dec. 23 at 11:52 PM
$LMNR $METC $PATH $GTIM $NERV AFTER-HOURS MOVERS: Currently Higher: - Ramaco Resources (METC) up 6.6% after announcing $100M buyback - UiPath (PATH) up 5.1% after admission into S&P MidCap 400 Currently Lower After Earnings: - Good Times Restaurants (GTIM) down 1.5% - Limoneira (LMNR) down 0.9% Currently Also Lower: - Minerva Neurosciences (NERV) down 3.9% after selling stock for holders - Organogenesis Holdings (ORGO) down 0.1% after initiating rolling submission of BLA to FDA for ReNu
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 12 at 6:22 PM
$NERV former runner showing signs of reversal. Daily MACD is triggering a buy signal. If volume comes in, the move could be strong.
0 · Reply
juanagustin2086
juanagustin2086 Nov. 30 at 6:57 PM
0 · Reply
Doozio
Doozio Nov. 29 at 4:48 PM
Da $NERV to think Roger won’t come rocking 🐒🍌🧠⏰♾️
0 · Reply
Kingcrab3333
Kingcrab3333 Nov. 21 at 12:40 PM
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 20 at 7:17 AM
$NERV just sit and watch the show😶‍🌫️
0 · Reply
Mg_1970
Mg_1970 Nov. 19 at 2:51 PM
$NERV Yesterday Inside Bar ...continuation buy signal at breakout of 4.48-4.5 😎😎👊
0 · Reply
Pbonk
Pbonk Nov. 17 at 6:56 PM
$NERV . Minerva said it raised $80 million upfront through a private financing round backed by LEADING HEALTHCARE INVESTORS.
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 17 at 4:13 PM
$NERV avg unit price 4.23. 50K shares LFG .. target to hold for two more weeks.
0 · Reply
Mg_1970
Mg_1970 Nov. 17 at 3:15 PM
$CMCT $NERV Halt 😍😍😎
0 · Reply